Edition:
United Kingdom

miRagen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

8.16USD
4:28pm GMT
Change (% chg)

$0.12 (+1.49%)
Prev Close
$8.04
Open
$8.10
Day's High
$8.26
Day's Low
$8.06
Volume
7,822
Avg. Vol
41,914
52-wk High
$17.83
52-wk Low
$6.65

Chart for

About

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product... (more)

Overall

Beta: 1.97
Market Cap(Mil.): $202.81
Shares Outstanding(Mil.): 21.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Miragen Therapeutics reports third quarter financial results

* Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update

08 Nov 2017

BRIEF-Miragen Therapeutics presents new data suggesting positive impact from systemically administered MRG-106

* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting

13 Oct 2017

BRIEF-Miragen Therapeutics presents new MRG-201 preclinical data

* Miragen Therapeutics presents new MRG-201 preclinical data for Inhaled Microrna-29 Mimic Targeting Pulmonary Fibrosis Source text for Eikon: Further company coverage:

11 Sep 2017

BRIEF-Miragen Therapeutics Q2 loss per share $0.34

* Miragen Therapeutics reports second quarter 2017 financial results and provides corporate update

11 Aug 2017

Earnings vs. Estimates